Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
08 05 2021
Historique:
received: 28 11 2019
accepted: 04 02 2020
entrez: 9 5 2021
pubmed: 10 5 2021
medline: 15 12 2021
Statut: ppublish

Résumé

European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016-2018. The main objective was to determine whether the 2016 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice. The method used was a cross-stional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed ≥ 6 months after the start of medication. A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 ± 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index ≥30 kg/m2) and 63.8% centrally obese (waist circumference ≥88 cm for women, ≥102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%. The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial.

Sections du résumé

BACKGROUND
European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016-2018. The main objective was to determine whether the 2016 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice.
METHODS
The method used was a cross-stional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed ≥ 6 months after the start of medication.
RESULTS
A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 ± 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index ≥30 kg/m2) and 63.8% centrally obese (waist circumference ≥88 cm for women, ≥102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%.
CONCLUSION
The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial.

Identifiants

pubmed: 33966079
pii: 6272716
doi: 10.1177/2047487320908698
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-379

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Kornelia Kotseva (K)

St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
National Institute for Prevention and Cardiovascular Health, National University of Ireland-Galway, Republic of Ireland.

Guy De Backer (G)

National Institute for Prevention and Cardiovascular Health, National University of Ireland-Galway, Republic of Ireland.

Dirk De Bacquer (D)

Department of Public Health and Primary Care, Ghent University, Belgium.

Lars Rydén (L)

Department of Medicine Solna, Karolinska Institutet, Sweden.

Arno Hoes (A)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.

Diederick Grobbee (D)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.

Aldo Maggioni (A)

Maria Cecilia Hospital, GVMCare & Research Cotignola, Italy.
EURObservational Research Programme, European Society of Cardiology, France.

Pedro Marques-Vidal (P)

Department of Medicine, Lausanne University Hospital, Switzerland.

Catriona Jennings (C)

National Institute for Prevention and Cardiovascular Health, National University of Ireland-Galway, Republic of Ireland.

Ana Abreu (A)

Hospital Santa Marta, Centro Hospitalar de Lisboa Central, Portugal.

Carlos Aguiar (C)

Hospital Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Portugal.

Jolita Badariene (J)

Clinic of Cardiac and Vascular Diseases, Vilnius University, Lithuania.
Centre of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Lithuania.

Jan Bruthans (J)

Center for Cardiovascular Prevention, Charles University in Prague, Czech Republic.

Renata Cifkova (R)

Center for Cardiovascular Prevention, Charles University in Prague, Czech Republic.

Kairat Davletov (K)

Health Research Institute, Al-Farabi Kazakh National University, Kazakhstan.

Mirza Dilic (M)

Medical Faculty, University of Sarajevo, Bosnia and Herzegovina.

Maryna Dolzhenko (M)

Supyk National Medical Academy of Postgraduate Education, Ukraine.

Dan Gaita (D)

Clinica de Recuperare Cardiovasculara, Universitatea de Medicina si Farmacie Victor Babes, Romania.

Nina Gotcheva (N)

Department of Cardiology, National Heart Hospital, Bulgaria.

Hosam Hasan-Ali (H)

Cardiovascular Medicine Department, Assiut University, Egypt.

Piotr Jankowski (P)

I Department of Cardiology, Interventional Electro-cardiology and Hypertension, Jagiellonian University Medical College, Poland.

Christos Lionis (C)

Clinic of Social and Family Medicine, University of Crete, Greece.

Silvia Mancas (S)

Clinica de Recuperare Cardiovasculara, Universitatea de Medicina si Farmacie Victor Babes, Romania.

Davor Milićić (D)

School of Medicine, University of Zagreb, Croatia.

Erkin Mirrakhimov (E)

Kyrgyz State Medical Academy, Kyrgyzstan.
National Center of Cardiology and Internal Medicine named after academician Mirrakhimov MM, Kyrgyzstan.

Rafael Oganov (R)

National Research Center for Preventive Medicine, Russia.

Nana Pogosova (N)

National Medical Research Center of Cardiology, Ministry of Healthcare of the Russian Federation, Russia.

Željko Reiner (Ž)

University Hospital Centre Zagreb, University of Zagreb, Croatia.

Duško Vulić (D)

Faculty of Medicine, University of Banja Luka, Bosnia and Herzegovina.

David Wood (D)

National Institute for Prevention and Cardiovascular Health, National University of Ireland-Galway, Republic of Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH